Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma
Abstract
:1. Introduction
2. Method
2.1. Expression Level of PPRC1
2.2. Prognostic Role of PPRC1
2.3. Correlation of PPRC1 and Tumor Immune Cells
2.4. Relationship between PPRC1 with Checkpoint Genes and Tumor-Stemness Index
2.5. Statistical Analysis
3. Results
3.1. Expression Patterns of PPRC1 in Pan-Cancer
3.2. Prognostic Role of PPRC1 in Pan-Cancer
3.3. Correlation of PPRC1 and Immune Cells
3.4. Relationship between PPRC1 Expression and Immune-Checkpoint Genes
3.5. Relationship between PPRC1 Expression and Tumor-Stemness Score
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Miller, K.D.; Ortiz, A.P.; Pinheiro, P.S.; Bandi, P.; Minihan, A.; Fuchs, H.E.; Martinez Tyson, D.; Tortolero-Luna, G.; Fedewa, S.A.; Jemal, A.M.; et al. Cancer statistics for the US Hispanic/Latino population, 2021. CA Cancer J. Clin. 2021, 71, 466–487. [Google Scholar] [CrossRef] [PubMed]
- Byrd, D.R.; Brierley, J.D.; Baker, T.P.; Sullivan, D.C.; Gress, D.M. Current and future cancer staging after neoadjuvant treatment for solid tumors. CA Cancer J. Clin. 2021, 71, 140–148. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Yu, S.; Feng, C.; Mao, D.; Li, J.; Zhu, X. In Situ Analysis of Cancer Cells Based on DNA Signal Amplification and DNA Nanodevices. Crit. Rev. Anal. Chem. 2021, 51, 8–19. [Google Scholar] [CrossRef] [PubMed]
- Urbanek-Trzeciak, M.O.; Galka-Marciniak, P.; Nawrocka, P.M.; Kowal, E.; Szwec, S.; Giefing, M.; Kozlowski, P. Pan-cancer analysis of somatic mutations in miRNA genes. EBioMedicine 2020, 61, 103051. [Google Scholar] [CrossRef]
- Liu, J.; Wang, Y.; Yin, J.; Yang, Y.; Geng, R.; Zhong, Z.; Ni, S.; Liu, W.; Du, M.; Yu, H.; et al. Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy. J. Oncol. 2022, 2022, 3477148. [Google Scholar] [CrossRef]
- Luo, C.; Widlund, H.R.; Puigserver, P. PGC-1 Coactivators: Shepherding the Mitochondrial Biogenesis of Tumors. Trends Cancer 2016, 2, 619–631. [Google Scholar] [CrossRef]
- Puigserver, P.; Wu, Z.; Park, C.W.; Graves, R.; Wright, M.; Spiegelman, B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92, 829–839. [Google Scholar] [CrossRef]
- Singh, F.; Zoll, J.; Duthaler, U.; Charles, A.L.; Panajatovic, M.V.; Laverny, G.; McWilliams, T.G.; Metzger, D.; Geny, B.; Krähenbühl, S.; et al. PGC-1β modulates statin-associated myotoxicity in mice. Arch. Toxicol. 2019, 93, 487–504. [Google Scholar] [CrossRef]
- Chambers, J.M.; Wingert, R.A. PGC-1α in Disease: Recent Renal Insights into a Versatile Metabolic Regulator. Cells 2020, 9, 2234. [Google Scholar] [CrossRef]
- Victorino, V.J.; Barroso, W.A.; Assunção, A.K.; Cury, V.; Jeremias, I.C.; Petroni, R.; Chausse, B.; Ariga, S.K.; Herrera, A.C.; Panis, C.; et al. PGC-1β regulates HER2-overexpressing breast cancer cells proliferation by metabolic and redox pathways. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2016, 37, 6035–6044. [Google Scholar] [CrossRef]
- Li, Y.; Kasim, V.; Yan, X.; Li, L.; Meliala, I.T.S.; Huang, C.; Li, Z.; Lei, K.; Song, G.; Zheng, X.; et al. Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation. Theranostics 2019, 9, 7599–7615. [Google Scholar] [CrossRef]
- Wang, H.; Yan, X.; Ji, L.Y.; Ji, X.T.; Wang, P.; Guo, S.W.; Li, S.Z. miR-139 Functions as An Antioncomir to Repress Glioma Progression Through Targeting IGF-1 R, AMY-1, and PGC-1β. Technol. Cancer Res. Treat. 2017, 16, 497–511. [Google Scholar] [CrossRef]
- Mori, M.P.; Souza-Pinto, N.C. PPRC1, but not PGC-1α, levels directly correlate with expression of mitochondrial proteins in human dermal fibroblasts. Genet. Mol. Biol. 2020, 43 (Suppl. 1), e20190083. [Google Scholar] [CrossRef]
- Cribbs, A.P.; Terlecki-Zaniewicz, S.; Philpott, M.; Baardman, J.; Ahern, D.; Lindow, M.; Obad, S.; Oerum, H.; Sampey, B.; Mander, P.K.; et al. Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism. Proc. Natl. Acad. Sci. USA 2020, 117, 6056–6066. [Google Scholar] [CrossRef]
- Tsai, H.F.; Chang, Y.C.; Li, C.H.; Chan, M.H.; Chen, C.L.; Tsai, W.C.; Hsiao, M. Type V collagen alpha 1 chain promotes the malignancy of glioblastoma through PPRC1-ESM1 axis activation and extracellular matrix remodeling. Cell Death Discov. 2021, 7, 313. [Google Scholar] [CrossRef]
- Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. Omics A J. Integr. Biol. 2012, 16, 284–287. [Google Scholar] [CrossRef]
- Mou, C.; Liu, B.; Wang, M.; Jiang, M.; Han, T. PGC-1-related coactivator (PRC) is an important regulator of microglia M2 polarization. J. Mol. Neurosci. MN 2015, 55, 69–75. [Google Scholar] [CrossRef]
- Ge, R.; Fang, H.F.; Chang, Y.Q.; Li, Z.; Liu, C.F. Clinicopathological features of polymorphous low-grade neuroepithelial tumor of the young. Zhonghua Bing Li Xue Za Zhi Chin. J. Pathol. 2020, 49, 1131–1135. [Google Scholar]
- Cui, G.; Wang, C.; Lin, Z.; Feng, X.; Wei, M.; Miao, Z.; Sun, Z.; Wei, F. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer. Bioengineered 2021, 12, 4828–4840. [Google Scholar] [CrossRef]
- Malta, T.M.; Sokolov, A.; Gentles, A.J.; Burzykowski, T.; Poisson, L.; Weinstein, J.N.; Kamińska, B.; Huelsken, J.; Omberg, L.; Gevaert, O.; et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 2018, 173, 338–354.e315. [Google Scholar] [CrossRef]
- Hou, G.X.; Liu, P.; Yang, J.; Wen, S. Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter. PLoS ONE 2017, 12, e0174515. [Google Scholar] [CrossRef] [PubMed]
- Lv, Z.; Qi, L.; Hu, X.; Mo, M.; Jiang, H.; Fan, B.; Li, Y. Zic Family Member 2 (ZIC2): A Potential Diagnostic and Prognostic Biomarker for Pan-Cancer. Front. Mol. Biosci. 2021, 8, 631067. [Google Scholar] [CrossRef] [PubMed]
- Lei, X.; Lei, Y.; Li, J.K.; Du, W.X.; Li, R.G.; Yang, J.; Li, J.; Li, F.; Tan, H.B. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2020, 470, 126–133. [Google Scholar] [CrossRef]
- Soularue, E.; Lepage, P.; Colombel, J.F.; Coutzac, C.; Faleck, D.; Marthey, L.; Collins, M.; Chaput, N.; Robert, C.; Carbonnel, F. Enterocolitis due to immune checkpoint inhibitors: A systematic review. Gut 2018, 67, 2056–2067. [Google Scholar] [CrossRef] [PubMed]
- Hargadon, K.M.; Johnson, C.E.; Williams, C.J. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 2018, 62, 29–39. [Google Scholar] [CrossRef]
- Hoos, A. Development of immuno-oncology drugs—From CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 2016, 15, 235–247. [Google Scholar] [CrossRef]
- Lytle, N.K.; Barber, A.G.; Reya, T. Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer 2018, 18, 669–680. [Google Scholar] [CrossRef]
- Huss, J.M.; Torra, I.P.; Staels, B.; Giguère, V.; Kelly, D.P. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol. Cell. Biol. 2004, 24, 9079–9091. [Google Scholar] [CrossRef]
- Alaynick, W.A. Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion 2008, 8, 329–337. [Google Scholar] [CrossRef]
- Kemper, M.F.; Zhao, Y.; Duckles, S.P.; Krause, D.N. Endogenous ovarian hormones affect mitochondrial efficiency in cerebral endothelium via distinct regulation of PGC-1 isoforms. J. Cereb. Blood Flow Metab. 2013, 33, 122–128. [Google Scholar] [CrossRef]
- Anderson, N.R.; Minutolo, N.G.; Gill, S.; Klichinsky, M. Macrophage-Based Approaches for Cancer Immunotherapy. Cancer Res. 2021, 81, 1201–1208. [Google Scholar] [CrossRef]
- Wei, F.; Zhang, T.; Deng, S.C.; Wei, J.C.; Yang, P.; Wang, Q.; Chen, Z.P.; Li, W.L.; Chen, H.C.; Hu, H.; et al. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Lett. 2019, 450, 1–13. [Google Scholar] [CrossRef]
- Santoni, M.; Massari, F.; Montironi, R.; Battelli, N. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. Biochim. Biophys. Acta Rev. Cancer 2021, 1876, 188547. [Google Scholar] [CrossRef]
- Giese, M.A.; Hind, L.E.; Huttenlocher, A. Neutrophil plasticity in the tumor microenvironment. Blood 2019, 133, 2159–2167. [Google Scholar] [CrossRef]
- Lee, Y.S.; Radford, K.J. The role of dendritic cells in cancer. Int. Rev. Cell Mol. Biol. 2019, 348, 123–178. [Google Scholar]
- Swann, J.B.; Smyth, M.J. Immune surveillance of tumors. J. Clin. Investig. 2007, 117, 1137–1146. [Google Scholar] [CrossRef]
- Li, B.; Chan, H.L.; Chen, P. Immune Checkpoint Inhibitors: Basics and Challenges. Curr. Med. Chem. 2019, 26, 3009–3025. [Google Scholar] [CrossRef]
- Iwai, Y.; Hamanishi, J.; Chamoto, K.; Honjo, T. Cancer immunotherapies targeting the PD-1 signaling pathway. J. Biomed. Sci. 2017, 24, 26. [Google Scholar] [CrossRef]
- Chen, D.; Menon, H.; Verma, V.; Guo, C.; Ramapriyan, R.; Barsoumian, H.; Younes, A.; Hu, Y.; Wasley, M.; Cortez, M.A.; et al. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: Retrospective analysis of two single-institution prospective trials. J. Immunother. Cancer 2020, 8, e000492. [Google Scholar] [CrossRef]
- Zeng, D.; Li, M.; Zhou, R.; Zhang, J.; Sun, H.; Shi, M.; Bin, J.; Liao, Y.; Rao, J.; Liao, W. Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. Cancer Immunol. Res. 2019, 7, 737–750. [Google Scholar] [CrossRef]
Clinicopathological Characteristics | Ovarian Cancer (Overall Survival, n = 1657) | Liver Cancer (Overall Survival, n = 364) | ||||
---|---|---|---|---|---|---|
N | HR | p-Value | N | HR | p-Value | |
Stage | ||||||
1 | 107 | 2.51 (0.75–8.34) | 0.12 | 170 | 0.74 (0.4–1.37) | 0.34 |
2 | 61 | 6.21 (1.96–19.72) | 0.0004 | 83 | 0.48 (0.21–1.07) | 0.065 |
3 | 1044 | 1.11 (0.94–1.31) | 0.22 | 83 | 2.22 (1.12–4.4) | 0.02 |
4 | 176 | 1.7 (1.1–2.62) | 0.015 | 4 | Ns | Ns |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ruan, X.; Cui, G.; Li, C.; Sun, Z. Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma. Medicina 2023, 59, 784. https://doi.org/10.3390/medicina59040784
Ruan X, Cui G, Li C, Sun Z. Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma. Medicina. 2023; 59(4):784. https://doi.org/10.3390/medicina59040784
Chicago/Turabian StyleRuan, Xingqiu, Guoliang Cui, Changyu Li, and Zhiguang Sun. 2023. "Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma" Medicina 59, no. 4: 784. https://doi.org/10.3390/medicina59040784